AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly's Trading Volume Surges 45.68% to 27.40 Billion, Ranks 20th in Market as it Acquires SiteOne Therapeutics for Up to 1 Billion
Generated by AI AgentAinvest Volume Radar
Tuesday, May 27, 2025 8:00 pm ET1min read
On May 27, 2025, Eli Lilly's trading volume reached 27.40 billion, marking a 45.68% increase from the previous day, placing it 20th in the day's stock market rankings.
Eli Lilly has agreed to acquire
, a privately held biopharma company, for up to $1 billion in cash. This acquisition includes an upfront payment and subsequent milestone payments. The deal brings SiteOne's flagship product, STC-004, a Phase 2 ready Nav1.8 inhibitor, into Eli Lilly's pipeline. STC-004 is being developed as a non-opioid-based pain treatment, aiming to advance new medicines for pain management.With this acquisition,
gains access to a promising non-opioid pain treatment, which aligns with the company's strategy to expand its pain management pipeline. The addition of STC-004 to Eli Lilly's portfolio is expected to enhance its capabilities in developing innovative pain management solutions.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Aptiv Slides 1.39% as Institutional Sells Clash with Strong Q3 Earnings and NYSE Volume Ranks 497th
Dec.22 2025
Diamondback Energy Gains 0.22% Despite 489th Volume Rank as Earnings Outperformance and Strategic Asset Sales Bolster Investor Confidence
Dec.22 2025
Kinross Gold's 2.66% Surge Despite 45.31% Volume Drop, 452nd in Market Activity Rank
Dec.22 2025
ATI Shares Rise 2.19% Despite 46% Volume Drop, Ranks 478th in Trading Activity
Dec.22 2025
United Therapeutics Shares Drop 0.65% Amid Insider and Institutional Selling, Trading Volume Ranks 465th
Dec.22 2025
Aime Insights
What is the current sentiment towards safe-haven assets like gold and silver?
How might the recent executive share sales at Rimini Street impact investor sentiment towards the company?
How could Nvidia's planned shipment of H200 chips to China in early 2026 affect the global semiconductor market?
How should investors position themselves in the face of a potential market correction?
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet